Skip to content

Mandala Painting During Chemotherapy

The Effect of Mandala Painting During Chemotherapy on Anxiety, Nausea, and Comfort Levels

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07269340
Enrollment
73
Registered
2025-12-08
Start date
2025-09-09
Completion date
2026-05-07
Last updated
2026-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Chemotherapy, Comfort, Mandala Painting, Nursing Care, Vomiting

Brief summary

In addition to managing drug side effects that arise during cancer treatment, maintaining the patient's psychosocial well-being is also very important. Therefore, the aim of this project is to examine the effect of mandala painting during chemotherapy on anxiety, nausea, and comfort levels. This project aims to reduce the negative effects of chemotherapy, such as nausea, anxiety, and decreased comfort, by distracting the patient's attention through the non-invasive and non-pharmacological practice of mandala coloring in patients undergoing chemotherapy. Mandala painting is a distraction and positive focus practice. A limited number of studies conducted on cancer patients have shown that it reduces distress and improves psychological well-being. However, no study in the literature has comprehensively addressed the symptoms experienced by patients during chemotherapy, such as anxiety, nausea, intense stress, and impaired comfort. The research will be conducted on patients undergoing chemotherapy for the first time, and patients in the experimental group will engage in mandala coloring for at least 30 minutes. Data obtained from assessments conducted before and after chemotherapy will be compared with control group data. This project will provide a more comprehensive assessment of the effect of mandala painting, a non-pharmacological intervention, on the negative symptoms of patients undergoing chemotherapy for the first time. In addition to its scientific contribution, it is believed that effective symptom management can contribute to patients' well-being. Furthermore, if nausea can be controlled, the need for antiemetics during treatment can be reduced. This will also contribute to reducing unwanted drug effects and lowering costs.

Interventions

art therapy: mandala painting

Sponsors

Uludag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \> 18 years old, * Receiving chemotherapy for the first time

Exclusion criteria

* Have a lower education level than secondary school (The STAI is appropriate for those who have at least a sixth-grade reading level), * Diagnosed with psychiatric and neurological diseases, * Diagnosed with dementia, * Received chemotherapy treatment more than once, * Planned to receive radiotherapy treatment together with chemotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline Anxiety levelbaseline, 60-120 minuteBaseline and post-intervention anxiety level assessed by trained research nurse using Spielberg's State-Trait Anxiety Inventory (STAI). The test scores between 20 and 80, with higher scores indicating more generalized and stronger anxiety.

Secondary

MeasureTime frameDescription
Nausea levelbaseline, 60-120 minuteBaseline and post-intervention nausea level assessed by trained research nurse using VAS (0 to 10; 0 means no nausea,10 means severe nausea).
Satisfaction level60-120 minutePost-intervention satisfaction level assessed by trained research nurse using VAS (0 to 10; 0 means not satisfied, 10 means very satisfied).
Comfort levelbaseline, 60-120 minuteBaseline and post-intervention comfort level assessed by trained research nurse using Distress Thermometer (0 to 10; 0 means no distress,10 means extreme distress).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026